UHRF1和P53在结肠癌中的表达及临床意义

doi:10.3760/cma.j.issn.1673422X.2016.05.007

摘要/Abstract

摘要： 目的探讨结肠癌组织中泛素样含PHD和环指域1(UHRF1)、P53蛋白的表达及其临床意义。方法采用免疫组织化学法检测70例结肠癌组织和30例癌旁正常组织中UHRF1、P53蛋白的表达情况，分析两者在结肠癌发生发展中的相关性，及其与结肠癌患者临床病理特征和预后的关系。结果UHRF1和P53在结肠癌癌组织中表达均明显高于癌旁正常组织(87.1%∶56.7%，χ2=11.366，P=0.001；64.3%∶6.7%，χ2=27.988，P=0.000)，且两者在结肠癌中的表达呈正相关(r=0.248，P=0.038)。UHRF1、P53蛋白在结肠癌中的表达与肿瘤TNM分期(χ2=4.426，P=0.049；χ2=6.000，P=0.016)、浸润深度(χ2=12.553，P=0.002；χ2=4.904，P=0.036)密切相关，与患者年龄(χ2=0.473，P=0.494；χ2=0.090，P=0.799)、性别（χ2=2.297，P=0.166；χ2=0.512，P=0.617）、肿瘤大小(χ2=0.638，P=0.481；χ2=2.392，P=0.215)、分化程度(χ2=2.088，P=0.352；χ2=0.303，P=0.859)无关。KaplanMeier曲线提示，UHRF1、P53均阳性表达患者的中位生存时间为21.83个月，较单独UHRF1阳性表达者（24.49个月）短（Z=-0.624，P=0.533)，前两者中位生存时间明显较UHRF1阴性表达者（37.33个月）短（Z=-2.856，P=0.004；Z=－2.694，P=0.007）。结论UHRF1、P53在结肠癌中均呈高表达，二者与结肠癌的发生发展密切相关，其表达强度可以作为患者预后的重要指标。

关键词: 结肠肿瘤, 肿瘤抑制蛋白质p53, 泛素样含PHD和环指域1

Abstract: ObjectiveTo investigate the expression levels and clinical significances of ubiquitinlike with PHD and ring finger domains 1 (UHRF1) and P53 in colon carcinoma. MethodsThe expressions of UHRF1 and P53 in 70 colon cancer tissues and 30 normal colon ones were detected by means of immunohistochemistry to analyze the correlation of these two proteins in the occurrence and development of colon carcinoma, and the relationship between their expressions and clinicopathological factors as well as prognosis was discussed. ResultsThe expression levels of UHRF1 and P53 in cancer tissues were significantly higher than those of canceradjacent tissues (87.1% vs. 56.7%, χ2=11.366, P=0.001; 64.3% vs. 6.7%, χ2=27.988, P=0.000) and showed a positive correlation between the two proteins (r=0.248, P=0.038). Both UHRF1 and P53 were associated with TNM stages (χ2=4.426, P=0.049; χ2=6.000, P=0.016) and the depth of invasion (χ2=12.553, P=0.002; χ2=4.904, P=0.036). However, they were irrelevant with the age (χ2=0.473, P=0.494; χ2=0.090, P=0.799) and gender (χ2=2.297, P=0.166; χ2=0.512, P=0.617) of patients, as well as the size (χ2=0.638, P=0.481; χ2=2.392, P=0.215) and histological grading of tumors (χ2=2.088, P=0.352; χ2=0.303, P=0.859). KaplanMeier analysis showed that the median survival time of patients with UHRF1, P53 positive expression was 21.83 months that was lower than patients with UHRF1 positive expression of 24.49 months (Z=－0.624, P=0.533). Both former of which was distinctly lower than that of negative ones of 37.33 months (Z=－2.856, P=0.004; Z=－2.694, P=0.007). ConclusionBoth UHRF1 and P53 are highly expressed in colon cancer tissues, which imply that UHRF1 and P53 may be strongly related with colon cancer development and can be a predictor for colon cancer prognosis.

Key words: Colon neoplasms, Tumor suppressor protein p53, Ubiquitinlike with PHD and ring finger domains 1

艾晓晴,贾喜花,王晓博,郑淑君,赵霞,张丙信. UHRF1和P53在结肠癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2016, 43(5): 346-349.

Ai Xiaoqing, Jia Xihua, Wang Xiaobo, Zheng Shujun, Zhao Xia, Zhang Bingxin. Expressions of UHRF1, P53 and their clinical significances in colon carcinoma[J]. Journal of International Oncology, 2016, 43(5): 346-349.

参考文献

［1］ Kurkjian C, Kummar S, Murgo AJ. DNA methylation: its role in cancer development and therapy［J］. Curr Probl Cancer, 2008, 32(5): 187-235. DOI: 10.1016/j.currproblcancer.2008.08.002. ［2］ Obata Y, Furusawa Y, Endo TA, et al. The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells［J］. Nat Immunol, 2014, 15(6): 571-579. DOI: 10.1038/ni.2886. ［3］ Nishiyama A, Yamaguchi L, Sharif J, et al. Uhrf1dependent H3K23 ubiquitylation couples maintenance DNA methylation and replication［J］. Nature, 2013, 502(7470): 249-253. DOI: 10.1038/nature12488. ［4］ Tien AL, Senbanerjee S, Kulkarni A, et al. UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis［J］. Biochem J, 2011, 435(1): 175-185. DOI: 10.1042/BJ20100840. ［5］ Chae HD, Kim SY, Park SE, et al. p53 and DNAdependent protein kinase catalytic subunit independently function in regulating actin damageinduced tetraploid G1 arrest［J］. Exp Mol Med, 2012, 44(3): 236-240. DOI: 10.3858/emm.2012.44.3.018. ［6］ Mudbhary R, Hoshida Y, Chernyavskaya Y, et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma［J］. Cancer Cell, 2014, 25(2): 196-209. DOI: 10.1016/j.ccr.2014.01.003. ［7］ Kim MY, Park SJ, Shim JW, et al. Naphthazarin enhances ionizing radiationinduced cell cycle arrest and apoptosis in human breast cancer cells［J］. Int J Oncol, 2015, 46(4): 1659-1666. DOI: 10.3892/ijo.2015.2857. ［8］ Geng Y, Gao Y, Ju H, et al. Diagnostic and prognostic value of plasma and tissue ubiquitinlike, containing PHD and RING finger domains 1 in breast cancer patients［J］. Cancer Sci, 2013, 104(2): 194-199. DOI: 10.1111/cas.12052. ［9］周碧芳, 邓斐, 周学惠, 等. UHRF1基因在人卵巢癌细胞株OVCAR3中的表达及意义［J］. 现代妇产科进展, 2012, 21(10): 748-751. ［10］ Wang F, Yang YZ, Shi CZ, et al. UHRF1 promotes cell growth and metastasis through repression of p16(ink4a) in colorectal cancer［J］. Ann Surg Oncol, 2012, 19(8): 2753-2762. DOI: 10.1245/s1043401121941. ［11］ Jones PA, Baylin SB. The epigenomics of cancer［J］. Cell, 2007, 128(4): 683-692. DOI: 10.1016/j.cell.2007.01.029 . ［12］ Fleuriel C, Touka M, Boulay G, et al. HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumors［J］. Int J Biochem Cell Biol, 2009, 41(1): 26-33. DOI: 10.1016/j.biocel.2008.05.028. ［13］ Arima Y, Hirota T, Bronner C, et al. Downregulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1dependent DNAdamage checkpoint signals contributes to cell cycle arrest at G1/S transition［J］. Genes Cells, 2004, 9(2): 131-142.

[1]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[2]	来比江·吾斯曼, 曹博威, 张文斌, 高华. 外源性AGR2对结肠癌细胞增殖及侵袭能力的影响[J]. 国际肿瘤学杂志, 2022, 49(2): 73-78.
[3]	李倩倩, 朱晓娣, 赵荣兰, 彭效祥. P2X7受体在结肠癌进展中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 250-253.
[4]	刘瑾, 陈翔, 马群, 童东东. DNA甲基转移酶1和叉头蛋白转录因子O亚型3a在结肠癌中的表达关系研究[J]. 国际肿瘤学杂志, 2021, 48(12): 735-738.
[5]	刘新德, 乔雷, 黄哲, 李云泽, 冯勇. 结肠癌术中使用雷替曲塞腹腔灌注化疗的近期疗效及安全性分析[J]. 国际肿瘤学杂志, 2020, 47(8): 501-504.
[6]	周慧萍, 李宇华, 王宇晖, 苏义龙, 杨营营, 徐笑天, 段小群. 常见植物药对结肠癌的防治作用及其作用机制[J]. 国际肿瘤学杂志, 2020, 47(1): 51-55.
[7]	赵高传, 陈卿奇, 庞莉, 程正, 麦芳奇. miR-205及miR-221在结肠癌患者血清中的水平及其临床意义[J]. 国际肿瘤学杂志, 2019, 46(9): 526-530.
[8]	于学娟, 安宏伟, 孙亚梅, 姜政, 张学海, 杨文敬, 张伟. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义 [J]. 国际肿瘤学杂志, 2019, 46(12): 718-722.
[9]	袁扬军, 卢大松, 邓柄取. CIAPIN1蛋白在结肠癌中的表达及其与肿瘤病理学特征的关系[J]. 国际肿瘤学杂志, 2018, 45(8): 483-486.
[10]	沈庆林，宋启斌，章必成，姚颐，徐唐鹏，褚玉新，彭敏. 微小RNA-134调控P53对非小细胞肺癌细胞增殖及凋亡的影响[J]. 国际肿瘤学杂志, 2018, 45(11): 647-651.
[11]	黄江, 张生军, 白利杰, 常琦. 结肠癌根治术患者围手术期血清癌胚抗原水平下降与患者预后的关系[J]. 国际肿瘤学杂志, 2017, 44(8): 662-667.
[12]	黄虞，杜冀晖，龚慧，王秀，王磊，李一凡. miR-92a调控KLF4表达影响结肠癌细胞增殖的机制研究[J]. 国际肿瘤学杂志, 2017, 44(11): 812-818.
[13]	万丽娟，陈明卫. 胰岛素抵抗相关因子与结肠癌干细胞的关系[J]. 国际肿瘤学杂志, 2017, 44(10): 790-793.
[14]	甘亚平, 郭晓花, 张君彧, 许晴晴, 吴疆, 王任勇, 邱敏, 蒋汝刚, 刘复兴, 宁志丰. 结肠癌COLO耐药株的构建及其与肿瘤干细胞的关系[J]. 国际肿瘤学杂志, 2016, 43(8): 646-650.
[15]	王建勋，曾甜，张鹏，王治刚，雷海录. NDRG2基因对结肠癌细胞SW620增殖和侵袭力的影响[J]. 国际肿瘤学杂志, 2016, 43(6): 401-404.